Open AccessThe Women's Health Initiative Estrogen-alone Trial had differential disease and medical expenditure consequences across age groups
Author(s) -
Macarius Donneyong,
Tsung-Chou Chang,
Joshua A. Roth,
McKenna Guilds,
Daniel Ankrah,
Mehdi Najafzadeh,
Wendy Xu,
Rowan T. Chlebowski,
Karen L. Margolis,
JoAnn E. Manson
Publication year - 2020
Publication title -
menopause
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.086
H-Index - 103
eISSN - 1530-0374
pISSN - 1072-3714
DOI - 10.1097/gme.0000000000001517
Subject(s) - medicine , population , women's health initiative , medical expenditure panel survey , disease , randomized controlled trial , clinical trial , gerontology , demography , health care , physical therapy , environmental health , observational study , health insurance , economic growth , economics , sociology
The Women's Health Initiative (WHI) randomized trial identified age differences in the benefit-risk profile of estrogen-alone (ET) use. The impact of WHI trial on disease-associated medical expenditures attributable to subsequent decreased ET utilization has, however, not been measured. Therefore, the objective of this analysis was to quantify the age-specific disease-associated medical expenditures attributable to reduced ET utilization after the WHI Hormone Therapy (HT) trials.